Skip to main content
Premium Trial:

Request an Annual Quote

Prometheus, Bayer Schering in Cancer PGx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories said today that it has struck a license and development agreement with Bayer Schering Pharma for oncology diagnostics that could net Prometheus as much as $160 million.

Under the non-exclusive agreement, which includes up-front and milestone payments, San Diego-based Prometheus will use its oncology diagnostic platform, which measures expression and activation of specific cancer pathways, to develop oncology tools that could be used to advance and personalize novel cancer therapeutics.

A functional pathway analysis using Prometheus' technology "could allow for a comprehensive analysis of the tumor, patient stratification, and efficacy predictability of individual targeted cancer therapeutics as well as most effective treatment combinations," Bayer Schering Pharma's Head of Global Drug Discovery, Andreas Busch, said in a statement. "Developing such a diagnostic tool constitutes a significant step towards personalized medicine in cancer treatment and we are convinced this will increasingly become the standard of clinical care in oncology."

Prometheus said that the deal could be worth up to $160 million if all drug candidates are successfully developed and obtain regulatory approval.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.